Profile of PANBELA THERAPEUTICS INC(NASDAQ:PBLA) stock

PANBELA THERAPEUTICS INC1.43

NASDAQ:PBLA (1/27/2023, 7:27:00 PM)-0.18 (-11.18%)

After market: 1.5 +0.07 (+4.9%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-10 2022-11-10/amc	Earnings (Next)	03-22 2023-03-22
Ins Owners	85.76%	Inst Owners	N/A
Market Cap	1.13M	Shares	792.80K
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	80
IPO	07-29 2014-07-29

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Panbela Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waconia, Minnesota and currently employs 4 full-time employees. The company went IPO on 2014-07-29. Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The firm is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.

Company Info

PANBELA THERAPEUTICS INC

712 Vista Blvd # 305

Waconia MINNESOTA 55387

P: 19524791196.0

CEO: Jennifer K. Simpson

Employees: 4

Website: https://panbela.com/about-us/company-overview/

PBLA News

9 hours ago - ChartmillWhich stocks are moving after the closing bell on Friday?

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

a day ago - ChartmillTop movers in Thursday's session

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.

2 days ago - ChartmillWhat's going on in today's session

Let's have a look at the top gainers and losers in the middle of the day of today's session.

2 days ago - ChartmillThese stocks are gapping in today's session

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

2 days ago - Seeking AlphaPanbela stock nosedives ~40% on pricing stock and warrants offering (NASDAQ:PBLA)

Panbela Therapeutics (PBLA) said Thursday it priced public offering of 6,675,000 shares of its common stock and warrants to purchase up to 13,350,000 shares.

2 days ago - Panbela Therapeutics, Inc.Panbela Announces Pricing of Approximately $15 Million Public Offering

PANBELA THERAPEUTICS INC (PBLA) 1.43 -0.18 (-11.18%)

1.43 -0.18 (-11.18%)